ArticleThe Kaohsiung journal of medical sciences2026
KAT2A Promotes the Progression of Renal Cell Carcinoma by Regulating the Succinylation of SERPINE2.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) and angiogenesis are critical drivers of renal cell carcinoma (RCC) progression, yet their upstream regulatory mechanisms remain incompletely understood. This study aimed to investigate the role of KAT2A in RCC and elucidate the underlying molecular mechanism by which it promotes tumor progression. To investigate KAT2A and SERPINE2 in RCC, we assessed their expression and downstream effects using real-time quantitative PCR and western blot. EMT markers (E-cadherin, N-cadherin, Vimentin) and SERPINE2 succinylation were also measured. Functional assays (CCK-8, colony formation, transwell, tube formation) evaluated cell viability, proliferation, migration, and angiogenesis. Co-localization (immunofluorescence) and interaction (co-immunoprecipitation) of KAT2A and SERPINE2 were confirmed. Finally, Ki-67, KAT2A, and SERPINE2 expression in RCC tumors were examined via immunohistochemistry. We identified that KAT2A expression was significantly elevated in RCC tissues and correlated with poor patient prognosis. Functionally, KAT2A depletion markedly inhibited RCC cell proliferation, migration, EMT, and HUVECs angiogenesis in vitro, as well as suppressed tumor growth in vivo. Mechanistically, KAT2A directly interacted with SERPINE2 and promoted its succinylation at lysine 158 (K158). This post-translational modification enhanced SERPINE2 protein stability, and SERPINE2 overexpression effectively reversed the tumor-suppressive effects induced by KAT2A silencing. Our findings reveal that the KAT2A/SERPINE2 axis is a key regulator of RCC pathogenesis, identifying KAT2A-mediated SERPINE2 succinylation as a novel mechanism and potential therapeutic target for RCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.